<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0871-9721</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Imunoalergologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Imunoalergologia]]></abbrev-journal-title>
<issn>0871-9721</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Alergologia e Imunologia Clínica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0871-97212023000100031</article-id>
<article-id pub-id-type="doi">10.32932/rpia.2023.03.101</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Controlo a longo prazo da dermatite atópica em doentes sob terapêutica com dupilumab - Um estudo multicêntrico]]></article-title>
<article-title xml:lang="en"><![CDATA[Long-term control of atopic dermatitis in patients treated with dupilumab - A multicentric study]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Limão]]></surname>
<given-names><![CDATA[Rita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Brás]]></surname>
<given-names><![CDATA[Rita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Neto]]></surname>
<given-names><![CDATA[Marta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernandes]]></surname>
<given-names><![CDATA[Rosa Anita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Abreu]]></surname>
<given-names><![CDATA[Cristina Lopes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[Célia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cosme]]></surname>
<given-names><![CDATA[Joana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[Fátima]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendes]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[Amélia Spínola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[Manuel Branco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pedro]]></surname>
<given-names><![CDATA[Elisa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[Anabela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Hospitalar Universitário Lisboa Norte Hospital Santa Maria Serviço de Imunoalergologia]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Pedro Hispano Unidade de Imunoalergologia ]]></institution>
<addr-line><![CDATA[Matosinhos ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidade de Lisboa Faculdade de Medicina Clínica Universitária de Imunoalergologia]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2023</year>
</pub-date>
<volume>31</volume>
<numero>1</numero>
<fpage>31</fpage>
<lpage>43</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0871-97212023000100031&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212023000100031&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0871-97212023000100031&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Fundamentos:  A dermatite ato&#769;pica (DA) afeta significativamente a qualidade de vida dos doentes.  Objetivos:  Avaliar o controlo da doença a longo prazo em doentes com DA sob dupilumab (DUP) e a aplicabilidade e relevância do Atopic dermatitis control tool (ADCT) neste contexto.  Métodos:  Estudo observacional retrospetivo de doentes com DA seguidos em consulta de Imunoalergologia em 2 centros hospitalares, que completaram pelo menos 6 meses de DUP. O controlo da doença foi avaliado através do ADCT. Foram avaliadas correlações entre o ADCT e a duração da DA, scores de avaliação clínica SCORAD, EASI, DLQI, escalas numéricas (NRS) do prurido e sono, IgE total e eosinofilia. Analisamos a evolução destes scores e biomarcadores ao longo do tratamento relativamente ao valor basal (T0) e as diferenças entre os doentes bem e mal controlados relativamente a estas variáveis.  Resultados: Foram incluídos 29 doentes, 51,7% do género feminino, idade média de 35,6 anos, duração mediana da DA de 29 anos e duração média do DUP de 14 meses. De acordo com o ADCT, 12 doentes (41%) reportaram mau controlo da DA. Globalmente verificou-se uma redução significativa no EASI, SCORAD, NRS-prurido, NRS-sono e DLQI desde T0 até ao momento de avaliação do ADCT. O grupo dos doentes bem controlados de acordo com o ADCT apresentou redução significativa no valor mediano do SCORAD, EASI e DLQI independentemente da duração do tratamento. A mediana de IgE total diminuiu significativamente aos 6 e 12 meses de DUP. Doentes com mau controlo da DA, de acordo com o ADCT, apresentaram valores de IgE total basal inferiores e doentes com IgE total basal mais elevada tiveram uma melhoria mais acentuada no DLQI sob DUP.  Conclusões:  Neste estudo, 41% dos doentes reportaram mau controlo da DA de acordo com o ADCT. Verificou-se uma correlação positiva entre ADCT e SCORAD e DLQI avaliados no mesmo momento temporal. Valores de IgE total basal inferiores associaram-se a mau controlo da DA, de acordo com o ADCT.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background:  Atopic dermatitis (AD) significantly affects patients&#8217; quality of life.  Objectives:  To assess long-term disease control in AD patients receiving dupilumab (DUP) treatment and the applicability and relevance of the Atopic Dermatitis Control Tool (ADCT) in this context.  Methods:  A retrospective observational study of patients with AD followed in an immunoalergology outpatient clinic in 2 Hospital Centers, who completed at least 6 months of DUP. Disease control was assessed using the ADCT in a single moment. Correlations between ADCT and AD duration, severity assessment scores SCORAD, EASI, DLQI, numerical scales (NRS) of pruritus and sleep, total IgE and eosinophilia were evaluated. We analyzed the evolution of these scores and biomarkers over the course of treatment in relation to baseline (T0) and the diferences between well and poorly controlled patients for these variables.  Results:  29 patients were included, 51.7% female, mean age of 35,6 years, median AD duration of 29 years and mean duration of DUP of 14 months. According to ADCT, 12 patients(41%) reported poor AD control. Globally, there was a significant reduction in EASI, SCORAD, NRS-pruritis, NRS-sleep, and DLQI from T0 to the time of ADCT assessment. Patients well-controlled according to ADCT had a significant reduction in the median score of SCORAD, EASI, and DLQI irrespective of the duration of treatment. Median total IgE significantly decreased at 6 and 12 months of DUP. Patients with poor AD control according to the ADCT had lower baseline total IgE values and patients with higher baseline total IgE had a greater improvement in DLQI under DUP.  Conclusions: In this study, 41% of patients reported poor AD control according to the ADCT. There was a positive correlation between ADCT and SCORAD and DLQI evaluated at the same time point. Lower baseline total IgE values were associated with poor AD control according to ADCT.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Dermatite atópica]]></kwd>
<kwd lng="pt"><![CDATA[atopic dermatitis control tool]]></kwd>
<kwd lng="pt"><![CDATA[biomarcadores]]></kwd>
<kwd lng="pt"><![CDATA[dupilumab]]></kwd>
<kwd lng="pt"><![CDATA[tratamento]]></kwd>
<kwd lng="en"><![CDATA[Atopic dermatitis]]></kwd>
<kwd lng="en"><![CDATA[atopic dermatitis control tool]]></kwd>
<kwd lng="en"><![CDATA[biomarkers]]></kwd>
<kwd lng="en"><![CDATA[dupilumab]]></kwd>
<kwd lng="en"><![CDATA[treatment]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wollenberg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barbarot]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bieber]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Christen-Zaech]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Deleuran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fink-Wagner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus-based European guidelines for the treatment of atopic eczema (atopic dermatitis) in adults and children: part I]]></article-title>
<source><![CDATA[J Eur Acad Dermatol Venereol]]></source>
<year>2018</year>
<volume>32</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>657&#8209;82</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Odhiambo]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Clayton]]></surname>
<given-names><![CDATA[TO]]></given-names>
</name>
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Asher]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global variations in prevalence of eczema symptoms in children from ISAAC phase three]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2009</year>
<volume>124</volume>
<page-range>1251-8 e1223</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Singam]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rastogi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review and meta-analysis of the prevalence of adult-onset atopic dermatitis]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2019</year>
<volume>80</volume>
<page-range>1526-32-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williamson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Merritt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[De Benedetto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>2020</year>
<volume>182</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>47-54</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Werfel]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Allam]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Biedermann]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Eyerich]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gilles]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Guttman-Yassky]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cellular and molecular immunologic mechanisms in patients with atopic dermatitis]]></article-title>
<source><![CDATA[J Allergy Clin]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanifin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Rajka]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic features of atopic dermatitis]]></article-title>
<source><![CDATA[Acta Derm Venereol]]></source>
<year>1980</year>
<volume>92</volume>
<page-range>44-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wollenberg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barbarot]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bieber]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Christen-Zaech]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Deleuran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fink-Wagner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II]]></article-title>
<source><![CDATA[J Eur Acad Dermatol Venereol]]></source>
<year>2018</year>
<volume>32</volume>
<page-range>850-78</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Neto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Regateiro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Marcelino]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Campina]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical protocol of evaluation of adult patients with atopic dermatitis treated with Dupilumab]]></article-title>
<source><![CDATA[Rev Port Imunoalergologia]]></source>
<year>2019</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>135-45</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fargnoli]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Esposito]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrucci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Girolomoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Offidani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Patrizi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis]]></article-title>
<source><![CDATA[J Dermatolog Treat]]></source>
<year>2019</year>
<volume>28</volume>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Newsom]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bashyam]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Balogh]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Strowd]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New and emerging systemic treatments for atopic dermatitis]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2020</year>
<volume>80</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1041-52</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arie&#776;ns]]></surname>
<given-names><![CDATA[LFM]]></given-names>
</name>
<name>
<surname><![CDATA[van der Schaft]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bakker]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Balak]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Romeijn]]></surname>
<given-names><![CDATA[MLE]]></given-names>
</name>
<name>
<surname><![CDATA[Kouwenhoven]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2020</year>
<volume>75</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>116-26</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pariser]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Gadkari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bieber]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Margolis]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2020</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>367-76</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Eckert]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gadkari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mallya]]></surname>
<given-names><![CDATA[UG]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nelson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis]]></article-title>
<source><![CDATA[BMC Dermatol]]></source>
<year>2019</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<source><![CDATA[Sanofi Group e Regeneron Pharmaceuticals Inc]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbarot]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Auziere]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gadkari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Girolomoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Puig]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of atopic dermatitis in adults: Results from an international survey]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2018</year>
<volume>73</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1284-93</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drucker]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[WQ]]></given-names>
</name>
<name>
<surname><![CDATA[Sevetson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Block]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Qureshi]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The burden of atopic dermatitis: Summary of a report for the national eczema association]]></article-title>
<source><![CDATA[J Invest Dermatol]]></source>
<year>2017</year>
<volume>137</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-30</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Claire Junior]]></surname>
<given-names><![CDATA[Saint]]></given-names>
</name>
<name>
<surname><![CDATA[Cerqueira]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Qualidade de vida em crianças e adolescentes com dermatite atópica e seus cuidadores]]></article-title>
<source><![CDATA[Rev Port Imunoalergologia]]></source>
<year>2021</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-48</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sheng]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shao]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment]]></article-title>
<source><![CDATA[J Cell Mol Med]]></source>
<year>2019</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>2324-32</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gadkari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Blackburn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Moon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Piercy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shinde]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ghorayeb]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discordance between physicianand patient-reported disease severity in adults with atopic dermatitis: A US cross-sectional survey]]></article-title>
<source><![CDATA[Am J Clin Dermatol]]></source>
<year>2017</year>
<volume>18</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>825-35</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Staumont-Sallé]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Taieb]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Merhand]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shourick]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TheAtopic Dermatitis Control Tool : A high-performance tool for optimal support]]></article-title>
<source><![CDATA[Acta Derm Venereol]]></source>
<year>2021</year>
<volume>101</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>adv00618</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guttman-Yassky]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bissonnette]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ungar]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sua&#769;rez-Farin&#771;as]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ardeleanu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Esaki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2019</year>
<volume>143</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>155-72</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tamagawa-Mineoka]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Katoh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atopic dermatitis: Identification and management of complicating factors]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2020</year>
<volume>21</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2671</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
